News agencies

Boston Scientific Faces $470 Million Shortfall, Considers Business Unit Sale

Strategic Insights

Mar 31, 2010 — 1 min read

Boston Scientific Corp.'s shutdown of its defibrillator operation is projected to result in a significant $470 million shortfall over the next two years. According to analysts, the company may need to sell one of its non-core business units to make up for the losses. Wells Fargo Securities analyst Larry Biegelsen estimates that the halt is costing Boston Scientific $5 million a day, while St. Jude Medical Inc. and Medtronic Inc. pick up market share from the stalled competitor.

Key Takeaways:

Boston Scientific faces a projected $470 million shortfall due to the shutdown of its defibrillator operation over the next two years.
Wells Fargo Securities analyst Larry Biegelsen estimates the halt is costing Boston Scientific $5 million a day.
Analysts suggest selling the pain management (neuromodulation) or neurovascular intervention businesses to cover the losses.
The neuromodulation business alone could fetch up to $1.6 billion, with possible buyers including Johnson & Johnson or Abbott.
Selling the neuromodulation business would be a logical move, given its relatively low profitability and potential for quick fundraising.
BSX CEO Ray Elliott is likely to face pressure to consider reducing debt or improving liquidity, given the company's $2.7 billion in debt due in 2011.
The recall issue could be the catalyst for Elliott to consider selling a business unit.

Statistics:

Boston Scientific's projected $470 million shortfall over the next two years.
Wells Fargo Securities analyst Larry Biegelsen's estimate of $5 million a day in losses due to the defibrillator halt.
Estimated value of the neuromodulation business: up to $1.6 billion.
Estimated value of the neurovascular intervention business: up to $1 billion.
Boston Scientific's debt: approximately $2.7 billion due in 2011.

Sources:

Boston Globe - citing a report from Bloomberg News
Reuters news service
Gabelli Health and Wellness Trust Mutual Fund portfolio manager Jeff Jonas
FAF Advisors analyst Tim Nelson
Copyright 2010 Euclid Infotech, distributed by Contify.com.

The End of American Hypergrowth

For two centuries, the US economy grew by adding workers. That's over.

Healthcare's $5.3 Trillion Drag

How Medical Spending Became America's Biggest Productivity Tax

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Researchers at the Wuhan University of Technology in China have made significant progress in the field of nanotechnology, specifically in the area of nanoindentation. A novel electromagnetic shock treatment (EST) method has been developed to enhance the microscale mechanical properties of a titanium alloy, with promising results obtained through array-based

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients

Research investigators at the Zhengzhou Central Hospital Affiliated to Zhengzhou University have made groundbreaking discoveries on the role of gut microbiota in determining the efficacy of immunotherapy for colon cancer patients. The study, which was recently published in Biochimica et Biophysica Acta, reveals that specific bacterial species and microbial metabolites

Read more

The End of American Hypergrowth

Healthcare's $5.3 Trillion Drag

Breakthrough in Nanotechnology: Electromagnetic Shock Treatment Shows Promise

Gut Microbiota Plays Crucial Role in Immunotherapy Success for Colon Cancer Patients